 Biocept Inc NASDAQ:BIOC swung to a profit in its fourth-quarter thanks to its coronavirus COVID-19 testing driving revenue to 18.5 million. For the period ended December 31, 2020, the San Diego-based firm posted a profit of 1.9 million, or 0.14 per diluted share on 13.6 million weighted-average shares outstanding, compared to a loss of 5.7 million, or 1.97 per share on 2.9 million weighted-average shares outstanding a year earlier. 